Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

RAPT Therapeutics, Inc. (RAPT) Current Deferred Revenue (2020 - 2022)

RAPT Therapeutics (RAPT) has disclosed Current Deferred Revenue for 3 consecutive years, with $645000.0 as the latest value for Q1 2022.

  • Quarterly Current Deferred Revenue fell 79.43% to $645000.0 in Q1 2022 from the year-ago period, while the trailing twelve-month figure was $645000.0 through Mar 2022, down 79.43% year-over-year, with the annual reading at $1.0 million for FY2021, 75.2% down from the prior year.
  • Current Deferred Revenue hit $645000.0 in Q1 2022 for RAPT Therapeutics, down from $1.0 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $6.0 million in Q2 2020 to a low of $645000.0 in Q1 2022.
  • Historically, Current Deferred Revenue has averaged $3.3 million across 3 years, with a median of $3.1 million in 2021.
  • Biggest five-year swings in Current Deferred Revenue: crashed 45.62% in 2021 and later crashed 79.43% in 2022.
  • Year by year, Current Deferred Revenue stood at $4.1 million in 2020, then tumbled by 75.2% to $1.0 million in 2021, then crashed by 36.52% to $645000.0 in 2022.
  • Business Quant data shows Current Deferred Revenue for RAPT at $645000.0 in Q1 2022, $1.0 million in Q4 2021, and $1.5 million in Q3 2021.